The FDA has approved Cephalon’s Treanda (bendamustine HCl injection) for the treatment of chronic lymphocytic leukemia (CLL). Treanda is believed to induce apoptosis and mitotic catastrophe in CLL cells and was shown to have a higher overall response and longer progression-free survival than those treated with chlorambucil in an open-label study including 301 treatment-naïve patients. Cephalon expects to launch Treanda in April 2008.

For more information call (800) 896-5855 or visit